{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T12:10:28Z","timestamp":1723551028603},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"DOI":"10.7759\/cureus.66760","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T11:40:36Z","timestamp":1723549236000},"source":"Crossref","is-referenced-by-count":0,"title":["Factors Affecting Compliance and Visual Outcomes in Patients Receiving Intravitreal Bevacizumab Injections"],"prefix":"10.7759","author":[{"given":"Ozukhil","family":"Radhakrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tushar","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilesh","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khushboo","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/380439a0","article-title":"Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene","volume":"380","author":"Ferrara N","year":"1996","unstructured":"Ferrara N, Carver-Moore K, Chen H, et al.. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996, 380:439-42. 10.1038\/380439a0","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s1350-9462(02)00043-5","article-title":"Vascular endothelial growth factors and angiogenesis in eye disease","volume":"22","author":"Witmer AN","year":"2003","unstructured":"Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003, 22:1-29. 10.1016\/s1350-9462(02)00043-5","journal-title":"Prog Retin Eye Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.04.056","article-title":"Anti-vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside","volume":"123","author":"Campochiaro PA","year":"2016","unstructured":"Campochiaro PA, Aiello LP, Rosenfeld PJ. Anti-vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside. Ophthalmology. 2016, 123:S78-88. 10.1016\/j.ophtha.2016.04.056","journal-title":"Ophthalmology"},{"key":"ref4","article-title":"Bevacizumab","author":"Gerriets V","year":"2024","unstructured":"Gerriets V, Kasi A. Bevacizumab. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702980","article-title":"Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up","volume":"23","author":"Arevalo JF","year":"2009","unstructured":"Arevalo JF, Wu L, Sanchez JG, Maia M, Saravia MJ, Fernandez CF, Evans T. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye (Lond). 2009, 23:117-23. 10.1038\/sj.eye.6702980","journal-title":"Eye (Lond)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage","volume":"26","author":"Spaide RF","year":"2006","unstructured":"Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006, 26:275-8. 10.1097\/00006982-200603000-00004","journal-title":"Retina"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1866_19","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema","volume":"68","author":"Kelkar A","year":"2020","unstructured":"Kelkar A, Webers C, Shetty R, et al.. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J Ophthalmol. 2020, 68:2143-7. 10.4103\/ijo.IJO_1866_19","journal-title":"Indian J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.36481","article-title":"Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population","volume":"55","author":"Kumar A","year":"2007","unstructured":"Kumar A, Sinha S. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol. 2007, 55:451-5. 10.4103\/0301-4738.36481","journal-title":"Indian J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S248661","article-title":"Factors affecting compliance to anti-vascular endothelial growth factor treatment of diabetic macular edema in a cohort of Jordanian patients","volume":"14","author":"Abu-Yaghi NE","year":"2020","unstructured":"Abu-Yaghi NE, Abed AM, Khlaifat DF, et al.. Factors affecting compliance to anti-vascular endothelial growth factor treatment of diabetic macular edema in a cohort of Jordanian patients. Clin Ophthalmol. 2020, 14:921-9. 10.2147\/OPTH.S248661","journal-title":"Clin Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-023-02261-x","article-title":"Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis","volume":"12","author":"Shahzad H","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S, et al.. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Rev. 2023, 12:92. 10.1186\/s13643-023-02261-x","journal-title":"Syst Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.4577","article-title":"Association of visit adherence and visual acuity in patients with neovascular age-related macular degeneration: secondary analysis of the comparison of age-related macular degeneration treatment trial","volume":"138","author":"Ramakrishnan MS","year":"2020","unstructured":"Ramakrishnan MS, Yu Y, VanderBeek BL. Association of visit adherence and visual acuity in patients with neovascular age-related macular degeneration: secondary analysis of the comparison of age-related macular degeneration treatment trial. JAMA Ophthalmol. 2020, 138:237-42. 10.1001\/jamaophthalmol.2019.4577","journal-title":"JAMA Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.28003","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration","volume":"47","author":"Polat O","year":"2017","unstructured":"Polat O, \u0130nan S, \u00d6zcan S, Do\u011fan M, K\u00fcsbeci T, Yava\u015f GF, \u0130nan \u00dc\u00dc. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk J Ophthalmol. 2017, 47:205-10. 10.4274\/tjo.28003","journal-title":"Turk J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318176de48","article-title":"Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema","volume":"28","author":"Kook D","year":"2008","unstructured":"Kook D, Wolf A, Kreutzer T, et al.. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008, 28:1053-60. 10.1097\/IAE.0b013e318176de48","journal-title":"Retina"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.423","article-title":"Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results","volume":"23","author":"Sacu S","year":"2009","unstructured":"Sacu S, Michels S, Prager F, et al.. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond). 2009, 23:2223-7. 10.1038\/eye.2008.423","journal-title":"Eye (Lond)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.12.028","article-title":"Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up","volume":"114","author":"Arevalo JF","year":"2007","unstructured":"Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al.. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007, 114:743-50. 10.1016\/j.ophtha.2006.12.028","journal-title":"Ophthalmology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000390","article-title":"Intravitreal bevacizumab improves the clearance of vitreous haemorrhage and visual outcomes in patients with proliferative diabetic retinopathy","volume":"4","author":"Wirkkala J","year":"2019","unstructured":"Wirkkala J, Bloigu R, Hautala NM. Intravitreal bevacizumab improves the clearance of vitreous haemorrhage and visual outcomes in patients with proliferative diabetic retinopathy. BMJ Open Ophthalmol. 2019, 4:e000390. 10.1136\/bmjophth-2019-000390","journal-title":"BMJ Open Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/276266-factors-affecting-compliance-and-visual-outcomes-in-patients-receiving-intravitreal-bevacizumab-injections","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T11:40:41Z","timestamp":1723549241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/276266-factors-affecting-compliance-and-visual-outcomes-in-patients-receiving-intravitreal-bevacizumab-injections"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.66760","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,13]]}}}